Company intelligence / Profile preview

Quanovate Tech

San Francisco, California, United Statesshop.miracare.com ↗

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

Quanovate Tech’s flagship product “Mira” provides lab-grade at-home quantitative measurement of key fertility hormones with 99% accuracy proven in clinical trials. The device has been widely adopted by both consumers and clinics for fertility tracking and reproductive health management. Over 80,000 analyzers have been shipped globally with more than 30,000 reported pregnancies attributed to its use. Clinical studies are ongoing to further validate the correlation between urinary and serum hormone levels in IVF protocols.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

OB/GYN and IVF clinics using the device for patient monitoringno major pharma partnerships disclosed

Beyond the preview

Go deeper on Quanovate Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quanovate Tech.

Explore the full profile